Paxil Articles
UK's OFT accuses GlaxoSmithKline of "market abuse"
19 April 2013
GlaxoSmithKline sells US penicillin facility and products to India’s Dr Reddy’s; GSK favored in Paxil trial
24 November 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
$28 Million Paxil settlement proposed
30 March 2009
Court rules against Par in Pentech litigation
16 February 2009
Lexapro and Zoloft are "best" antidepressants
9 February 2009
Stock Commentary - New York week to Jan 12, 2009
19 January 2009
GSK Paxil settlement
13 October 2008
Stock Commentary - Europe - week to June 16, 2008
23 June 2008
GSK faces renewed scrutiny over Paxil as unsealed study claims firm "improperly" counted placebo cases
23 June 2008
Stock Commentary - Europe - week to Oct 29, 2007
5 November 2007
GSK and Mylan settle Paxil IP dispute
29 October 2007
Caraco gets FDA OK for generic Paxil
9 July 2007
Letter from the Editor; GSK rebuke over Seroxat trial
5 February 2007
GSK settles US Paxil suit with $63.8M payout
6 November 2006
2005: "difficult year for SkyePharma," chairman
24 April 2006
Canada: branded drugs slip, generics grow
27 March 2006
Andrx' 4th-qtr 2005 income drops 16%
27 March 2006
GSK updates Paxil warnings
19 December 2005
Stock Commentary - Europe - week to Aug 15
5 September 2005
Teva gets OK for generic Paxil
22 August 2005
US FDA posts DSOB meeting summary
15 August 2005
GSK EPS rises 10% on 6% sales growth
8 August 2005
GlaxoSmithKline sees 10% EPS rise on 6% sales growth
1 August 2005
GSK's Paxil returns to US market
4 July 2005
Stock Commentary - Europe
16 May 2005
SkyePharma sees 17% 1st-qtr turnover hike
9 May 2005
GSK to resume Paxil/Avandamet production in Puerto Rico?
28 April 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
Rising tide of litigation against pharma from govt, states and whistleblowers, FDLI told
25 April 2005
GSK updates on US drug seizures
11 April 2005
FDA halts distribution of two GSK drugs
14 March 2005
St John's Wort as effective as paroxetine
28 February 2005
Alpharma and Synthon to co-promote Pexeva
24 January 2005
GSK responds to CHMP opinion on use of Seroxat
20 December 2004
GSK gets off lightly with $2.5m settlement in Spitzer case
6 September 2004
Letter from the Editor
6 September 2004
Editor's views on Sanofi-Aventis
16 August 2004
Par sees 2nd-qtr 2004 sales rocket 83%
9 August 2004
GSK's 2nd-qtr 2004 EPS drops 12%
2 August 2004
Merck KGaA lifts 2004 forecast on strong qtr
2 August 2004
Stock Commentary - Europe
28 June 2004
Letter from the Editor
28 June 2004
UK Seroxat law suit "weeks away"
28 June 2004
GSK must withdraw Paxil TV ad, says FDA
21 June 2004
GSK clarifies status of paroxetine trial data
21 June 2004
News from ASCO; GSK under fire; Editorial
14 June 2004
Stock Commentary - Europe
14 June 2004
UK DoH to sue GSK over Seroxat data?
14 June 2004
Stock Commentary - New York
31 May 2004
New York City sues GSK over Paxil patents
24 May 2004
SkyePharma's full-year 2003 sales down 24%
10 May 2004
GSK's 1st-qtr profit continues decline
10 May 2004
Merck KGaA's organic pharma sales up 4.3%
3 May 2004
Lexapro as effective as Paxil for GAD
22 March 2004
California seniors sue GSK over Paxil
22 March 2004
GSK's Paxil CR gets FDA OK for new use
1 March 2004
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
GSK's 2003 results slightly below consensus forecasts
16 February 2004
US DoJ to appeal FDA generics ruling
16 February 2004
GSK's Paxil CR cleared in Canada
19 January 2004
GSK's Paxil CR cleared by FDA for new use
27 October 2003
GlaxoSmithKline reports 24% 3rd qtr earnings growth
27 October 2003
GSK's Paxil losing ground fast, says IMS
6 October 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
